September 27, 2016 12:10 AM ET

Biotechnology

Company Overview of NGM Biopharmaceuticals, Inc.

Company Overview

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutics for the treatment of cardio-metabolic diseases, liver diseases, and cancer. It offers NGM282, a protein variant of FGF19 for the treatment of bile acid related diseases (BARD) and non-alcoholic steatohepatitis (NASH); NGM386 and NGM395, protein variants of NP201 developed for the treatment of metabolic conditions, such as type 2 diabetes, obesity, and NASH; and NGM313, an agonistic antibody of the beta-klotho (KLB)/FGFR1c pathway. NGM Biopharmaceuticals, Inc. has strategic partnerships with Merck, MedImmune, and JDRF. The company was incorporated in 2007 and is based in S...

630 Gateway Boulevard

South San Francisco, CA 94080-7014

United States

Founded in 2007

Phone:

650-243-5555

Fax:

650-583-1646

Key Executives for NGM Biopharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
President
Age: 43
Founder, Chief Scientific Officer and Director
Age: 53
Chief Financial Officer
Chief Operating Officer and Vice President
Compensation as of Fiscal Year 2016.

NGM Biopharmaceuticals, Inc. Key Developments

NGM Biopharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-16-2016 01:55 PM

NGM Biopharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-16-2016 01:55 PM. Venue: Le Parker Meridien, New York, New York, United States.

NGM Biopharmaceuticals, Inc. Presents at 36th Annual Canaccord Genuity Growth Conference 2016, Aug-10-2016 03:00 PM

NGM Biopharmaceuticals, Inc. Presents at 36th Annual Canaccord Genuity Growth Conference 2016, Aug-10-2016 03:00 PM. Venue: InterContinental Hotel, Boston, Massachusetts, United States.

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and Nash

NGM Bio reported initiation of a Phase 1 trial of NGM313 in overweight or obese volunteers. NGM313 is an agonistic antibody engineered to selectively activate the beta-klotho (KLB)-FGFR1c receptor complex and promote beneficial metabolic activity. NGM313 was discovered and is being developed by NGM Bio as a potential treatment for type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Under the terms of a collaboration agreement with Merck Sharp and Dohme Corp. ("Merck") executed in 2015, Merck has an exclusive, one-time option to license NGM313 following completion of a human proof of concept study. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability and pharmacokinetic profile of NGM313 after single and multiple ascending doses. The study will also measure a variety of biomarkers associated with metabolic regulation. Data from the trial are expected in 2017.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NGM Biopharmaceuticals, Inc., please visit www.ngmbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.